AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18182669 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable DNA index in HR patients
Number of subjects: 1744
Study 16181380 — intervention group
Group type: COMPARATOR
Intervention: Detection of methylated DNA in HLTF
Number of subjects: 49
Study 16181380 — intervention group
Group type: COMPARATOR
Intervention: Detection of methylated DNA in hMLH1
Number of subjects: 49
Study 16181380 — intervention group
Group type: COMPARATOR
Intervention: Detection of methylated DNA in APC
Number of subjects: 49
Study 16181380 — intervention group
Group type: COMPARATOR
Intervention: Overall detection of methylated DNA in at least one marker
Number of subjects: 49
Study 16181380 — intervention group
Group type: COMPARATOR
Intervention: Detection of methylation in two markers
Number of subjects: 49
Study 16181380 — intervention group
Group type: COMPARATOR
Intervention: Detection of methylation in at least one marker
Number of subjects: 49
Study 14566763 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by a renal dietitian
Number of subjects: 56
Study 14566763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 10384893 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure with stimulus combination L1 = 65 dB, L1‐L2 = 25 dB, f2/f1 = 1.18
Number of subjects: 27
Study 10384893 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure with other stimulus combinations (L1 = 65 dB, L1‐L2 = 25 dB, f2/f1 = 1.22 and 1.20)
Number of subjects: 27
Study 10384893 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to noise)
Number of subjects: 27
Study 7479175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-SQ Array
Number of subjects: 20
Study 7479175 — intervention group
Group type: COMPARATOR
Intervention: Lead-alone
Number of subjects: 20
Study 2319048 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Control Treatment (PCT)
Number of subjects: 57
Study 2319048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 57
Study 2319048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2319048 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 57
Study 6766653 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg four times daily for 3 months)
Number of subjects: 19
Study 6766653 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 mg four times daily for 3 months)
Number of subjects: 19
Study 31918400 — intervention group
Group type: EXPERIMENTAL
Intervention: Social justice framing
Number of subjects: 3758
Study 31918400 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on children framing
Number of subjects: 3758
Study 30822774 — intervention group
Group type: EXPERIMENTAL
Intervention: F17464, 20 mg twice daily
Number of subjects: 134
Study 30822774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 28918213 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldrich score
Number of subjects: 98
Study 28918213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hasche score
Number of subjects: 98
Study 28918213 — intervention group
Group type: EXPERIMENTAL
Intervention: van Hellemond score
Number of subjects: 98
Study 28918213 — intervention group
Group type: COMPARATOR
Intervention: CMR
Number of subjects: 98
Study 25540069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative morphine guided by ANI
Number of subjects: 120
Study 25540069 — intervention group
Group type: COMPARATOR
Intervention: Control group (intraoperative morphine guided by anaesthetist with ANI concealed)
Number of subjects: 120
Study 23993224 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intravenous ketorolac preoperatively
Number of subjects: 85
Study 23993224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 85
Study 21813441 — intervention group
Group type: EXPERIMENTAL
Intervention: Active training treatment (strength training)
Number of subjects: 47
Study 19127194 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle change group
Number of subjects: 100
Study 19127194 — intervention group
Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 100
Study 17909351 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 66
Study 15099455 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-administered influenza vaccination
Number of subjects: 1865
Study 11309872 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation sedation (IHS)
Number of subjects: 88
Study 11309872 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 88
Study 9343033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propafenone (600 mg loading dose)
Number of subjects: 0
Study 9343033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8201510 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bovine lung surfactant extract (beractant), 4 doses
Number of subjects: 17
Study 8201510 — intervention group
Group type: COMPARATOR
Intervention: Air (control group), equal volume to surfactant group
Number of subjects: 17
Study 8201510 — intervention group
Group type: EXPERIMENTAL
Intervention: CDH infants
Number of subjects: 17
Study 2906778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (sublingual administration)
Number of subjects: 48
Study 28972663 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DLPDT)
Number of subjects: 46
Study 28972663 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (CPDT)
Number of subjects: 46
Study 27547851 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 (twice a week plyometric training)
Number of subjects: 16
Study 27547851 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 (twice a week plyometric training)
Number of subjects: 16
Study 27547851 — intervention group
Group type: COMPARATOR
Intervention: G1 and G2
Number of subjects: 16
Study 25062570 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral nutritional supplements
Number of subjects: 46
Study 25062570 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment with water or lemonade
Number of subjects: 46
Study 23739438 — intervention group
Group type: EXPERIMENTAL
Intervention: mydocalm
Number of subjects: 1700
Study 23739438 — intervention group
Group type: COMPARATOR
Intervention: control group (no mydocalm)
Number of subjects: 1700
Study 20004758 — intervention group
Group type: COMPARATOR
Intervention: Exercise 0 days/week
Number of subjects: 61
Study 20004758 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 2 days/week
Number of subjects: 61
Study 20004758 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 4 days/week
Number of subjects: 61
Study 20004758 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 7 days/week
Number of subjects: 61
Study 18225981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 547
Study 18225981 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus ceftazidime
Number of subjects: 547
Study 18225981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole and Vancomycin plus ceftazidime
Number of subjects: 547
Study 16625281 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bacterial prostatitis (CBPP)
Number of subjects: 70
Study 16625281 — intervention group
Group type: COMPARATOR
Intervention: Healthy adult volunteers (HAV)
Number of subjects: 70
Study 14659774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol/HDL-cholesterol (CHOL/HDL) in CAD patients
Number of subjects: 71
Study 14659774 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides (TG) in CAD patients
Number of subjects: 71
Study 10904184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea prepared from leaves of S. cumini
Number of subjects: 30
Study 10904184 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude extract prepared from leaves of S. cumini
Number of subjects: 30
Study 8737000 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 8737000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1572759 — intervention group
Group type: EXPERIMENTAL
Intervention: Test A
Number of subjects: 18
Study 1572759 — intervention group
Group type: EXPERIMENTAL
Intervention: Test B
Number of subjects: 18
Study 1572759 — intervention group
Group type: EXPERIMENTAL
Intervention: Test C
Number of subjects: 18
Study 3912186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 30 mg administered once daily before going to bed
Number of subjects: 27
Study 3912186 — intervention group
Group type: COMPARATOR
Intervention: Sustained release terbutaline 10 mg twice daily
Number of subjects: 27
Study 3912186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 30 mg administered once daily
Number of subjects: 27
Study 31145150 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0
Study 29144535 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet‐ and mobile‐supported occupational stress‐management intervention (iSMI) consisting of seven sessions and one booster session
Number of subjects: 264
Study 29144535 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC) with unrestricted access to treatment as usual
Number of subjects: 264
Study 27421672 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: intravenous administration of contrast material at a dose of 1mL/kg and CTA examinations at 100kV
Number of subjects: 101
Study 27421672 — intervention group
Group type: COMPARATOR
Intervention: Group B: intravenous administration of contrast material at a dose of 0.5mL/kg and CTA examinations at 80kV
Number of subjects: 101
Study 24045855 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein drink containing 15 g protein, twice a day
Number of subjects: 65
Study 24045855 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink, twice a day
Number of subjects: 65
Study 21790634 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion in symptomatic anemic premature neonates
Number of subjects: 52
Study 21790634 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SCOR in symptomatic subjects who improved after transfusion
Number of subjects: 52
Study 21790634 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SCOR in symptomatic subjects who did not improve after transfusion
Number of subjects: 52
Study 21790634 — intervention group
Group type: COMPARATOR
Intervention: Baseline SCOR in asymptomatic neonates
Number of subjects: 52
Study 21790634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline SCOR (≤ 0.73) in symptomatic subjects
Number of subjects: 52
Study 19326107 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics/synbiotics
Number of subjects: 733
Study 17998081 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepaid monetary incentive
Number of subjects: 3825
Study 17998081 — intervention group
Group type: EXPERIMENTAL
Intervention: Short questionnaire
Number of subjects: 3825
Study 17998081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no monetary incentive)
Number of subjects: 3825
Study 17998081 — intervention group
Group type: COMPARATOR
Intervention: Control group (long questionnaire)
Number of subjects: 3825
Study 15241753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm-based training
Number of subjects: 20
Study 15241753 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 20
Study 15241753 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants with hemiparesis)
Number of subjects: 20
Study 12269645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine (20 mg/day)
Number of subjects: 20
Study 12269645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg/day)
Number of subjects: 20
Study 12269645 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg/day)
Number of subjects: 20
Study 12269645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9636965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) cells from BOS patients
Number of subjects: 6
Study 9636965 — intervention group
Group type: EXPERIMENTAL
Intervention: BOS patients
Number of subjects: 6
Study 9636965 — intervention group
Group type: COMPARATOR
Intervention: Controls (unaffected recipients)
Number of subjects: 6
Study 8206064 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of piperacillin
Number of subjects: 0
Study 8206064 — intervention group
Group type: COMPARATOR
Intervention: Three doses of piperacillin
Number of subjects: 0
Study 2687897 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg bamyphylline
Number of subjects: 30
Study 2687897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29779220 — intervention group
Group type: EXPERIMENTAL
Intervention: Micrografts seeded onto collagen sponge (Test group, n=15)
Number of subjects: 29
Study 29779220 — intervention group
Group type: COMPARATOR
Intervention: Collagen sponge alone (Control group, n=14)
Number of subjects: 29
Study 26053680 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus a hypocaloric diet for 6 months (group A)
Number of subjects: 20
Study 26053680 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 20
Study 26233620 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarus Levitan fiberoptic stylet (FPS)
Number of subjects: 89
Study 26233620 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 89
Study 24041479 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyfit intervention for 2 months
Number of subjects: 284
Study 24041479 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 284
Study 20095806 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg glucocorticosteroids for 5 days
Number of subjects: 35
Study 20095806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg glucocorticosteroids for 5 days
Number of subjects: 35
Study 19029466 — intervention group
Group type: EXPERIMENTAL
Intervention: torcetrapib/atorvastatin
Number of subjects: 910
Study 19029466 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin monotherapy
Number of subjects: 910
Study 19029466 — intervention group
Group type: EXPERIMENTAL
Intervention: torcetrapib
Number of subjects: 910
Study 15737448 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral lower-limb amputees
Number of subjects: 18
Study 15737448 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied controls
Number of subjects: 18
Study 12633912 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 55
Study 12633912 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 55
Study 12633912 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 55
Study 12633912 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 55
Study 10880708 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 290
Study 8893393 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 12
Study 8893393 — intervention group
Group type: COMPARATOR
Intervention: Didanosine
Number of subjects: 12
Study 1985164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiation (1,800 cGy) and intrathecal methotrexate (RT group)
Number of subjects: 49
Study 1985164 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral methotrexate (MTX group)
Number of subjects: 49
Study 1985164 — intervention group
Group type: COMPARATOR
Intervention: Both RT and MTX groups
Number of subjects: 49
Study 6849644 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin sulfate (7.5 mg/kg, IM) - single dose
Number of subjects: 73
Study 6849644 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin sulfate (7.5 mg/kg, IM) - two doses (5 1/2 to 12 hours apart)
Number of subjects: 73
Study 6849644 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin sulfate (7.5 mg/kg, IM) - second dose given 9 to 12 hours after first
Number of subjects: 73
Study 31968080 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume (12 mL/kg)
Number of subjects: 18
Study 31968080 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume (6 mL/kg)
Number of subjects: 18
Study 31274110 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 872
Study 28892265 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen preemptive analgesia
Number of subjects: 89
Study 28892265 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 89
Study 28892265 — intervention group
Group type: COMPARATOR
Intervention: Thoracoscopy and laparoscopic surgery
Number of subjects: 89
Study 27147264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761® (240 mg daily)
Number of subjects: 61
Study 27147264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 25078578 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis
Number of subjects: 8
Study 25078578 — intervention group
Group type: COMPARATOR
Intervention: Superficial venous thrombolysis
Number of subjects: 8
Study 23011014 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic artemether/lumefantrine 20/120 mg tablets
Number of subjects: 0
Study 19414437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of ET‐A receptor blocker BQ‐123 (40 nmol/min, group A, n = 13)
Number of subjects: 26
Study 19414437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of ET‐A receptor blocker BQ‐123 (40 nmol/min) and ET‐B receptor blocker BQ‐788 (10 nmol/min, group AB, n = 13)
Number of subjects: 26
Study 19414437 — intervention group
Group type: COMPARATOR
Intervention: ET‐receptor blockade (both groups)
Number of subjects: 26
Study 16388944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hankison based FEV1/FVC interpretation
Number of subjects: 100
Study 16388944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hankison based FEV1/FEV6 interpretation
Number of subjects: 100
Study 16388944 — intervention group
Group type: COMPARATOR
Intervention: Morris predictive equations for FEV1/FVC
Number of subjects: 100
Study 12816266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (30,000 KIU/kg on induction and 10,000 KIU/kg/hr infusion until surgery completion, max 8 hours)
Number of subjects: 100
Study 12816266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12816266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 100
Study 11156281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined recovery (involving active and massage components)
Number of subjects: 18
Study 11156281 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 18
Study 11156281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined recovery
Number of subjects: 18
Study 11156281 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 18
Study 11156281 — intervention group
Group type: COMPARATOR
Intervention: Massage recovery
Number of subjects: 18
Study 8635612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose (75IU) human menopausal gonadotrophin (hMG)
Number of subjects: 164
Study 8635612 — intervention group
Group type: COMPARATOR
Intervention: Pure FSH
Number of subjects: 164
Study 1300037 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine (Cim)
Number of subjects: 20
Study 1300037 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ranitidine (Ran)
Number of subjects: 20
Study 1300037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6380485 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 12
Study 6380485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31892674 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agent with laser
Number of subjects: 50
Study 31892674 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agent only
Number of subjects: 50
Study 31892674 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo prescription)
Number of subjects: 50
Study 29199720 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1650 mg/m2 on RT days throughout the course of radiotherapy)
Number of subjects: 30
Study 29199720 — intervention group
Group type: COMPARATOR
Intervention: 5FU (500 mg/m2 on RT days #1‐#5 and #21‐#25)
Number of subjects: 30
Study 26341927 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60
Study 26341927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60
Study 26341927 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy age-matched)
Number of subjects: 60
Study 24488721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tideglusib 600 mg
Number of subjects: 37
Study 24488721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tideglusib 800 mg
Number of subjects: 37
Study 24488721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22167570 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (1 mg/kg)
Number of subjects: 0
Study 22167570 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (1 mg/kg)
Number of subjects: 0
Study 22167570 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (1 mg/kg)
Number of subjects: 0
Study 22167570 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and simvastatin in healthy human subjects
Number of subjects: 0
Study 22167570 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin in healthy human subjects
Number of subjects: 0
Study 19079942 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet
Number of subjects: 131
Study 19079942 — intervention group
Group type: EXPERIMENTAL
Intervention: LF diet
Number of subjects: 131
Study 19079942 — intervention group
Group type: COMPARATOR
Intervention: CTR diet
Number of subjects: 131
Study 17241782 — intervention group
Group type: EXPERIMENTAL
Intervention: BXL-628 (elocalcitol)
Number of subjects: 0